Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin/pioglitazone plus canagliflozin crossover study for ketone risk reduction in type 2 diabetes
ChiCTR2400083152Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin, pioglitazone and canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Serum ketone bodies and Hepatorenal function. Started Apr 2024; status: recruiting.
02
Drugs
metforminpioglitazonecanagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400083152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083152.